Le Lézard
Classified in: Business
Subject: ACC

Vesting of the All Employee Share Plan in Kindred Group plc


VALLETTA, Malta, Jan 2, 2019 /PRNewswire/ -- On 2 January 2019, 1,015 share awards from the All Employee Share Plan vested, using 1,015 SDRs from the Kindred Group's share buy-back programme.

Following the vesting of these awards, 3,533,120 SDRs from the share buy-back programmes continue to be held by Kindred Group. The total amount of issued shares in Kindred Group plc is 230,126,200 ordinary shares with a par value of GBP 0.000625. 

CONTACT:

For more information:

Inga Lundberg, Investor Relations, +44 788 799 6116

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/kindred-group/r/vesting-of-the-all-employee-share-plan-in-kindred-group-plc,c2708637

The following files are available for download:

https://mb.cision.com/Main/824/2708637/970951.pdf

PDF

 

 


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 20:39
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...

at 20:15
The partnership was unveiled internally at the Franchisor's annual convention in Las Vegas, NV in December 2023, eliciting...

at 19:35
Regenx Tech Corp., (the "Company" or "Regenx") is providing this bi-weekly update on the status of the application to the Alberta Securities Commission for a management cease trade order, under National Policy 12-203 -?? Management Cease Trade...

at 19:14
Kadestone Capital Corp. ("Kadestone" or the "Company") , a vertically integrated property company today announced its financial results for the year ended December 31, 2023....

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...



News published on and distributed by: